Unlocking Brazil: Pure Global's Guide to ANVISA's Clinical Data Requirements for SaMD in LATAM

This episode of LATAM MedTech Insights dives deep into the complex world of clinical data requirements for Software as a Medical Device (SaMD) seeking approval from Brazil's regulatory body, ANVISA. We unpack the critical regulation RDC 657/2022 and explain how ANVISA's risk-based classification system directly dictates the level of clinical evidence your company must provide. We explore the specific pathways for both low-risk and high-risk SaMD. Learn what kind of evidence can be used for simpler devices and understand the rigorous demands for more complex, high-impact software. We highlight common pitfalls and strategic considerations that can make or break your market entry into one of LATAM's most vital healthcare markets. A real-world scenario: Imagine your company has an AI diagnostic tool with successful FDA clearance based on US clinical trials. You're ready to launch in Brazil, but ANVISA puts your application on hold. They are questioning whether your data, collected from a predominantly Caucasian population, is valid for the ethnically diverse population of Brazil. Your launch is now delayed, and you face the unexpected cost of running a local validation study. Key Takeaways: * How does ANVISA's four-tier risk classification for SaMD directly impact your clinical data strategy? * Is your existing clinical data from the US or EU automatically sufficient for a Brazilian submission? * For low-risk SaMD, what are the alternatives to conducting a full clinical trial? * Why might ANVISA challenge world-class clinical data based on patient demographics? * What is a Brazil Registration Holder (BRH), and why is it a non-negotiable requirement for market access? * Under what specific circumstances is a dedicated, local clinical trial absolutely necessary for your SaMD? * How can you effectively leverage data from "equivalent devices" to strengthen your ANVISA submission? * What are the most common documentation and translation mistakes that lead to delays? Navigating the specifics of ANVISA's requirements can be overwhelming. At Pure Global, we provide end-to-end regulatory consulting for MedTech and IVD companies, combining deep local expertise in Brazil with advanced AI tools to streamline your path to market. From regulatory strategy and technical dossier submission to acting as your official Brazil Registration Holder, we manage the complexities so you can focus on growth. Contact us at [email protected] or visit https://pureglobal.com/ to streamline your market access to Brazil and beyond.